Erudio Healtherudio.com
Drug
Mezigdomide trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying mezigdomide: MELT-MM. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| MELT-MM NCT06645678 · YOUNGIL KOH | relapsed/refractory multiple myeloma | Phase 1/Phase 2 | 54 | 13 | Focused | Nov 5, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| SUCCESSOR-2 NCT05552976 · Bristol-Myers Squibb DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| SUCCESSOR-1 NCT05519085 · Celgene DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||